Trial finds weight loss drug taken monthly helps people lose 20% of body weight

A new trial revealed that a weight loss Drugs taken monthly helps people lose 20% of their body weight.

Weight loss drugs such as OzempicWegovy and Mounjaro have become popular and now there is a new GLP-1 medication, the maritide, which could be tested that could be competitive on the market.

The maritid, of the AMGEN medication manufacturer, is different from other weight loss drugs because it also has a monoclonal antibody, which allows the medication to stay in the body longer, NBC News Health and medical journalist Berkeley Lovelace Jr. explained in an article published on Monday.

The article plunges into a new test published in The New England Journal of Medicine. The researchers analyzed nearly 600 participants, who were divided into those with type 2 diabetes and obesity and those with obesity.

The test revealed that those who have obesity alone who were treated with maritid lost up to around 20% of their body weight, on average, after 52 weeks. Those who have obesity alone who did not take the maritide lost up to 2.6% of their body weight on average.

Participants who had diabetes and obesity lost up to 17% of their body weight, on average, while taking maritide, according to researchers. Those who suffer from the two diseases that were not on maritid lost up to 1.4% of their body weight, on average.

Ozempic and similar drugs can help patients lose 15 to 20% of their body weight, according to Department of Surgery of Columbia University. Ozempic drugs and other GLP-1s are taken every week, but the maritide has only to be taken monthly, which makes it more practical for patients.

“It is always easier for patients to have to take something once a month,” said Dr. Michelle Ponder, assistant medicine professor at the Duke University School of Medicine in North Carolinasaid to Lovelace.

Ponder, which was not part of the maritid test, added: “Many patients we see in endocrinology are diabetic patients, and therefore they would take several insulin blows a day.

Marititid researchers said gastrointestinal problems were “common” with the drug, but Lovelace stressed that the side effects of the drug were similar to that of other GLP-1 drugs.